Product Description: PLK1-IN-9 (Compound M2) is an inhibitor for polo-like kinase 1 (PLK1), that inhibits PLK proteins modified with peptides 1010pT, cdc25c and PBIP, with IC50s of 1.6, 0.8 and 1.4 μM, respectively. PLK1-IN-9 inhibits proliferations of cancer cells HeLa, HL60, SNU387/499, HepG2, exhibits cytotoxicity and induces apoptosis. PLK1-IN-9 inhibits tumor growth in HepG2 xenograft mouse model[1].
Formula: C12H7F3N4O2
References: [1]Kin K, et al., Pharmaceutical composition for preventing or treating cancer, containing activation inhibitor of plk1 as active ingredient. WO2020111325.
CAS Number: 893772-67-3
Molecular Weight: 296.20
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Polo-like Kinase (PLK)